Ticker Details
Xenon Pharmaceuticals Inc. Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its products portfolio includes Glybera, TV-45070.
IPO Date:	November 5, 2014
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$5.59B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.46 | 2.45%
Avg Daily Range (30 D):	$1.10 | 2.03%
Avg Daily Range (90 D):	$0.82 | 1.75%

Institutional Daily Volume
Avg Daily Volume:	.3M
Avg Daily Volume (30 D):	1.64M
Avg Daily Volume (90 D):	1.04M

Trade Size
Avg Trade Size (Sh.):	79
Avg Trade Size (Sh.) (30 D):	66
Avg Trade Size (Sh.) (90 D):	63

Institutional Trades
Total Institutional Trades:	2,897
Avg Institutional Trade:	$1.81M
Avg Institutional Trade (30 D):	$3.35M
Avg Institutional Trade (90 D):	$2.55M
Avg Institutional Trade Volume:	.05M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$2.24M
Avg Closing Trade (30 D):	$10.06M
Avg Closing Trade (90 D):	$5.85M
Avg Closing Volume:	59.56K

News

Mar 27, 2026 @ 11:03 PM Xenon Pharma Stock Up 55% as Insider Sells $78K in... Source: Jonathan Ponciano

Mar 11, 2026 @ 2:39 AM Xenon Pharmaceuticals Announces Pricing of Upsized... Source: Na

Feb 23, 2026 @ 3:18 PM Spyre Therapeutics Stock Surges This Past Year as ... Source: Jonathan Ponciano

Dec 4, 2025 @ 10:20 PM Xenon Pharmaceuticals Reports Inducement Grants Un... Source: Xenon Pharmaceuticals Inc.

Aug 1, 2025 @ 8:55 PM Xenon Pharmaceuticals Reports Inducement Grants Un... Source: Xenon Pharmaceuticals Inc.

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-4.36	$-1.31	$-4.36
Diluted EPS	$-4.36	$-1.31	$-4.36
Revenue	$7.5M	$M	$7.5M
Gross Profit
Net Income / Loss	$-345.91M	$-105.26M	$-345.91M
Operating Income / Loss	$-373.07M	$-109.77M	$-373.07M
Cost of Revenue
Net Cash Flow	$56.45M	$94.65M	$56.45M
PE Ratio